Memory Treatment Centers of Jacksonville specializes in the treatment of Alzheimer’s Disease and other forms of Dementia. We use the latest advancements in medical science to provide cutting-edge treatment to our patients while empowering them to take control of their healthcare decisions. We are committed to providing compassionate and comprehensive care to improve your quality of life and extend your independence.
Our team is comprised of experienced and dedicated healthcare professionals who are passionate about providing personalized care to patients. We understand that the needs of our patients and their loved ones are unique. As a result, our care team tailors treatment plans to suit the individual, while providing support for their loved ones. These treatment plans are developed with the guidance of the latest research and by adopting a holistic perspective that acknowledges the interplay between physical and mental well-being.
Furthermore, we are proud to work with families and caregivers to provide education and support, ensuring that our patients receive the best care possible.
At Memory Treatment Centers, we use the latest technology and advancements in medicine to develop a treatment plan tailored to your unique diagnosis.
We aim to identify the root cause of any cognitive impairments through an in-depth diagnostic process.
Once a diagnosis is reached, our care will create a comprehensive and holistic treatment plan that is tailored to each patient’s specific needs.
On January 6th, 2023, the FDA granted accelerated approval for Leqembi (Lecanemab) which is the second FDA-approved therapy for Alzheimer’s Disease.
Leqembi (Lecanemab) specifically targets protofibrils which cluster together and forms the protein plaque beta-amyloid 42.
Memory Treatment Centers is now actively infusing Leqembi.
Donanemab is a biologic infusion that is currently in trial to treat early symptoms of Alzheimer’s disease. Manufactured by Eli Lilly, Donanemab was designed by the FDA as a breakthrough treatment and is expecting approval from the FDA during the summer of 2023.